Welcome to our newsroom. Here you will find all the latest news about Bristol Myers Squibb in Belgium. As a journalist, you will also find all press releases, contact details and visual material here.
Bristol Myers Squibb today announced that the European Commission has approved Sotyktu (deucravacitinib), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy, representing a new way of treating this chronic immune-mediated disease.
On March 8th, we celebrated International Women’s Day. The focus this year is on gender equity and celebrating women telling their stories. The B-NOW Belgian Chapter was thrilled to invite BMS Braine-l’Alleud-based employees to its first Lunch & Learn session of the year.
Cancer treatments are getting better, more diverse and more numerous. Although we still die from cancer, we are also increasingly recovering from it. Research, pharmaceutical companies, governments and private individuals are joining forces to fight cancer together.
For all media inquiries
Sabine De Beuf
Head of Corporate Communications, Public Affairs & Patient Advocacy
Phone number: +32 2 352 76 11
If you are not a member of the press and have a non-media related question then find the right contact information here. This will enable us to help you faster!
Learn more about the mission, vision and values of Bristol Myers Squibb Belgium
More information about the medicines distributed by Bristol Myers Squibb in Belgium
Get an overview of our research for innovative medicines